Merck (MRK) Stock Analysis
This is a peer-relative look at Merck (MRK): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | MRK |
|---|---|
| Name | Merck & Co., Inc. |
| Country/Region | United States |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals |
| Market Capitalization | 370.89 billion USD |
| Currency | USD |
| Exchange | NYSE |
| Listing Date | January 2, 1962 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Total Return (1Y) | 84.84% | 48.26% |
| Total Return (3Y, Annualized) | 14.50% | 12.46% |
| Total Return (5Y, Annualized) | 17.86% | -4.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 30.44% | 67.21% |
| Beta (5Y) | 0.20 | 0.93 |
| Max Drawdown (5Y) | -43.44% | -82.64% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 2.65 | 0.78 |
| Sortino Ratio (1Y) | 5.06 | 1.30 |
Profitability
ROE (TTM)
Merck (MRK) posts ROE of 6.96%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96%
Group distribution
- Max
- 102.29%
- MRK
- 6.96%
- Q3
- 3.16%
- Median
- -32.34%
- Q1
- -64.79%
- Min
- -157.61%
Largest peers
- LLY
- 102.29%
- AMGN
- 91.47%
- NVS
- 30.35%
- JNJ
- 25.74%
- AZN
- 21.97%
- MRK
- 6.96%
- ABBV
- --
Net Margin (TTM)
Merck (MRK) keeps 4.77% of revenue as net profit, putting net margin in the upper peer quartile. After operating costs, interest, and taxes, more of each sales dollar reaches shareholders than it does at most industry peers.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.77%
Group distribution
- Max
- 12.02%
- MRK
- 4.77%
- Q3
- 2.44%
- Median
- 0.00%
- Q1
- -4.89%
- Min
- -13.51%
Largest peers
- LLY
- 33.53%
- AMGN
- 22.95%
- NVS
- 22.50%
- JNJ
- 21.48%
- AZN
- 17.02%
- ABBV
- 9.80%
- MRK
- 4.77%
Operating Margin (TTM)
Merck (MRK) has negative operating margin of -0.24%. Core operations were loss-making before interest and taxes over the trailing period.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.24%
Group distribution
- Max
- 76.04%
- Q3
- 10.45%
- Median
- 0.00%
- MRK
- -0.24%
- Q1
- -120.32%
- Min
- -308.66%
Largest peers
- LLY
- 54.22%
- ABBV
- 40.04%
- AMGN
- 35.55%
- NVS
- 34.62%
- JNJ
- 29.19%
- AZN
- 23.46%
- MRK
- -0.24%
Profitability Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| ROE (TTM) | 6.96% | -32.34% |
| ROA (TTM) | 11.87% | -14.69% |
| Net Margin (TTM) | 4.77% | 0.00% |
| Operating Margin (TTM) | -0.24% | 0.00% |
| Gross Margin (TTM) | 75.90% | 33.96% |
Growth
Revenue Growth
Merck (MRK) grew revenue 1.31%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.
EPS Growth
Merck (MRK) grew earnings per share 8.01%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.
Growth Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | 1.31% | 10.61% |
| Revenue Growth (3Y CAGR) | 3.12% | 10.96% |
| EPS Growth (YoY) | 8.01% | 3.16% |
| EPS Growth (3Y CAGR) | 8.43% | 3.62% |
Financial Strength
Current Ratio (MRQ)
Merck (MRK) has current ratio of 1.32, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
Group distribution
- Max
- 26.10
- Q3
- 12.34
- Median
- 5.72
- Q1
- 2.80
- MRK
- 1.32
- Min
- 0.10
Largest peers
- AMGN
- 1.37
- LLY
- 1.36
- MRK
- 1.32
- JNJ
- 1.09
- AZN
- 0.89
- NVS
- 0.86
- ABBV
- 0.81
Debt / Equity (MRQ)
Merck (MRK) has debt-to-equity ratio of 1.28, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.28
Group distribution
- Max
- 1.56
- MRK
- 1.28
- Q3
- 0.64
- Median
- 0.14
- Q1
- 0.02
- Min
- 0.00
Largest peers
- AMGN
- 4.90
- LLY
- 1.62
- MRK
- 1.28
- NVS
- 1.17
- AZN
- 0.64
- JNJ
- 0.58
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 1.32 | 5.72 |
| Debt / Equity (MRQ) | 1.28 | 0.14 |
| Net Debt / EBITDA | 1.62 | 1.15 |
Dividends
Dividend Yield (TTM)
Merck (MRK) has dividend yield of 2.18%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.18%
Group distribution
- MRK
- 2.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.86%
- ABBV
- 2.62%
- AMGN
- 2.21%
- MRK
- 2.18%
- AZN
- 1.96%
- JNJ
- 1.88%
- LLY
- 0.56%
Dividend Payout Ratio (TTM)
Merck (MRK) has payout ratio of 268.80%, meaning dividends exceeded current-period earnings. The gap would need to be covered by cash, retained earnings, financing, or other sources, so earnings alone do not support the payout.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
268.80%
Group distribution
- MRK
- 268.80%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 268.80%
- ABBV
- 190.40%
- NVS
- 71.60%
- AMGN
- 60.87%
- JNJ
- 60.79%
- AZN
- 47.41%
- LLY
- 21.69%
Dividend Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 2.18% | 0.00% |
| Dividend Payout Ratio (TTM) | 268.80% | 0.00% |
Valuation
P/E Ratio (TTM)
Merck (MRK) trades at P/E ratio of 120.26, above the peer range for its industry. The market is paying unusually heavily for TTM earnings relative to comparable companies.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
120.26
Group distribution
- MRK
- 120.26
- Max
- 83.73
- Q3
- 44.68
- Median
- 28.50
- Q1
- 15.51
- Min
- 0.14
Largest peers
- MRK
- 120.26
- ABBV
- 72.45
- LLY
- 38.61
- JNJ
- 31.97
- AMGN
- 27.17
- AZN
- 24.32
- NVS
- 24.17
P/S Ratio (TTM)
Merck (MRK) trades at 5.57 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.57
Group distribution
- Max
- 65.27
- Q3
- 29.50
- Median
- 7.31
- MRK
- 5.57
- Q1
- 3.49
- Min
- 0.01
Largest peers
- LLY
- 12.86
- ABBV
- 7.04
- JNJ
- 6.77
- AMGN
- 6.21
- MRK
- 5.57
- NVS
- 5.36
- AZN
- 4.11
P/B Ratio (MRQ)
Merck (MRK) trades at 8.85 on P/B ratio, in the higher book-value quartile. The market is paying a premium to book, so stronger ROE, cleaner assets, or a better growth profile need to justify it.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.85
Group distribution
- Max
- 15.46
- MRK
- 8.85
- Q3
- 7.32
- Median
- 4.02
- Q1
- 1.90
- Min
- -5.81
Largest peers
- LLY
- 30.24
- AMGN
- 20.22
- MRK
- 8.85
- JNJ
- 7.80
- NVS
- 7.32
- AZN
- 5.02
- ABBV
- -76.35
Valuation Metrics
| Metric | Current stock: MRK | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | 120.26 | 28.50 |
| P/S Ratio (TTM) | 5.57 | 7.31 |
| P/B Ratio (MRQ) | 8.85 | 4.02 |
| Free Cash Flow Yield (TTM) | 4.09% | -1.84% |